Please try another search
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China. It engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California.
Name | Age | Since | Title |
---|---|---|---|
Michael J. Donovan | 68 | - | Scientific Advisor |
Sara Barrington | 54 | 2020 | Non-Executive Director |
Paul Pagano | 38 | 2019 | CEO, Chief Scientific Officer & Executive Director |
Joshua D. Kuban | - | - | Scientific Advisor |
Ruth L. Katz | - | - | Scientific Advisor |
James R. McCullough | 54 | 2019 | Independent Non-Executive Director |
Andrew N. Boteler | 55 | 2021 | Senior Independent Non-Executive Director |
Steven M. Dubinett | - | - | Scientific Advisor |
Roy Davis | 65 | - | Independent Non-Executive Chairman |
Claudia Henschke | - | - | Scientific Advisor |
David F. Yankelevitz | - | - | Scientific Advisor |
Drew Moghanaki | - | 2022 | Scientific Advisor |
Max Rosen | - | - | Scientific Advisor |
David M. Anderson | 60 | - | CFO, Company Secretary & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review